Literature DB >> 21326960

In vitro susceptibility of Plasmodium falciparum to monodesethylamodiaquine, quinine, mefloquine and halofantrine in Abidjan (Côte d'Ivoire).

W Yavo1, K B Bla, A J Djaman, S B Assi, L K Basco, A Mazabraud, M Koné.   

Abstract

BACKGROUND: Malaria is the primary cause of hospitalization in Côte d'Ivoire. Early treatment is one of the strategies to control this illness. However, the spread of resistance of Plasmodium falciparum to antimalarial drugs can seriously compromise this strategy.
OBJECTIVES: The aim of this study was to assess the in vitro susceptibility of P. falciparum to monodesethylamodiaquine and aminoalcohols in Abidjan (Côte d'Ivoire).
METHODS: We assessed the in vitro susceptibility of isolates collected from patients with uncomplicated malaria by using the WHO optical microtest technique.
RESULTS: The proportions of resistance to monodesethylamodiaquine, méfloquine and halofantrine were 12.5%, 15.6% and 25.9%, respectively. For quinine, none of isolates showed evidence of in vitro resistance. However, two isolates (6.1%) had IC(50) values above 300 nM. The IC(50) of each drug was positively and significantly correlated to that of the other three drugs, and the correlation was higher between halofantrine and mefloquine.
CONCLUSIONS: Our results showed that the in vitro chloroquine resistance reported in previous studies has been extended to other antimalarial drugs investigated in this study except for quinine. Therefore, it is necessary to implement a long-term monitoring system of antimalarial drug resistance.

Entities:  

Keywords:  Abidjan (Côte d'Ivoire); Plasmodium falciparum; halofantrine; in vitro test; mefloquine; monodesethylamodiaquine; quinine

Mesh:

Substances:

Year:  2010        PMID: 21326960      PMCID: PMC2956299     

Source DB:  PubMed          Journal:  Afr Health Sci        ISSN: 1680-6905            Impact factor:   0.927


  30 in total

1.  [Senegal and malaria. True prophylactic failure of mefloquine].

Authors:  M Gari-Toussaint; B Pradines; V Mondain; A Keundjian; P Dellamonica; Y Le Fichoux
Journal:  Presse Med       Date:  2002-07-13       Impact factor: 1.228

2.  Monitoring of drug-resistant malaria in Africa.

Authors:  Pascal Ringwald; Tom Sukwa; Leonardo K Basco; Peter Bloland; Kamini Mendis
Journal:  Lancet       Date:  2002-09-14       Impact factor: 79.321

3.  Visual in-vitro test for determining the drug sensitivity of Plasmodium falciparum.

Authors:  K H Rieckmann
Journal:  Lancet       Date:  1982-06-12       Impact factor: 79.321

4.  In vitro sensitivity of Plasmodium falciparum to amodiaquine compared with other major antimalarials in Madagascar.

Authors:  M Randrianarivelojosia; J L Sahondra Harisoa; L P Rabarijaona; L A Raharimalala; L Ranaivo; V Pietra; J B Duchemin; F Rakotomanana; V Robert; P Mauclere; F Ariey
Journal:  Parassitologia       Date:  2002-12

5.  Response of Kampuchean strains of Plasmodium falciparum to antimalarials: in-vivo assessment of quinine and quinine plus tetracycline; multiple drug resistance in vitro.

Authors:  M Giboda; M B Denis
Journal:  J Trop Med Hyg       Date:  1988-08

6.  Susceptibility of Plasmodium falciparum strains to mefloquine in an urban area in Senegal.

Authors:  I Hatin; J F Trape; F Legros; J Bauchet; J Le Bras
Journal:  Bull World Health Organ       Date:  1992       Impact factor: 9.408

7.  Susceptibility of Plasmodium falciparum to the drugs used to treat severe malaria (quinine) and to prevent malaria (mefloquine, cycloguanil) in Comoros Union and Madagascar.

Authors:  Milijaona Randrianarivelojosia; Laurence Randrianasolo; Rindra V Randremanana; Arthur Randriamanantena; Arsène Ratsimbasoa; Jean-Désiré Rakotoson
Journal:  S Afr Med J       Date:  2004-01

8.  Molecular epidemiology of malaria in cameroon. IX. Characteristics of recrudescent and persistent Plasmodium falciparum infections after chloroquine or amodiaquine treatment in children.

Authors:  Leonardo K Basco; Mathieu Ndounga; Annick Keundjian; Pascal Ringwald
Journal:  Am J Trop Med Hyg       Date:  2002-02       Impact factor: 2.345

9.  [Antimalaria drug delivery in pharmacies in non-severe malaria treatment. A survey on the quality of the treatment: the case of Bouaké (Côte d'Ivoire)].

Authors:  Christiane Pulcherie Kiki-Barro; Firmin N'goran Konan; Willam Yavo; Richard Kassi; Eby Ignace Hervé Menan; Vincent Djohan; Moussa Koné
Journal:  Sante       Date:  2004 Apr-Jun

10.  In-vitro sensitivity of Plasmodium falciparum to chloroquine, halofantrine, mefloquine and quinine in Madagascar.

Authors:  M Randrianarivelojosia; A Ratsimbasoa; L Randrianasolo; A Randrianarijaona; R Jambou
Journal:  East Afr Med J       Date:  2002-05
View more
  3 in total

1.  In vitro susceptibility of Indian Plasmodium falciparum isolates to different antimalarial drugs & antibiotics.

Authors:  Pooja Agarwal; A R Anvikar; C R Pillai; Kumkum Srivastava
Journal:  Indian J Med Res       Date:  2017-11       Impact factor: 2.375

2.  Ex-vivo Sensitivity of Plasmodium falciparum to Common Anti-malarial Drugs: The Case of Kéniéroba, a Malaria Endemic Village in Mali.

Authors:  Karim Traoré; Seidina A S Diakité; Sekou Bah; Drissa S Konaté; Djeneba Dabitao; Ibrahim Sanogo; Modibo Sangaré; Souleymane Dama; Bourama Keita; Mory Doumbouya; Merepen A Guindo; Seydou Doumbia; Mahamadou Diakité
Journal:  Drugs R D       Date:  2020-09

3.  A SYBR Green 1-based in vitro test of susceptibility of Ghanaian Plasmodium falciparum clinical isolates to a panel of anti-malarial drugs.

Authors:  Neils B Quashie; Nancy O Duah; Benjamin Abuaku; Lydia Quaye; Ruth Ayanful-Torgby; George A Akwoviah; Margaret Kweku; Jacob D Johnson; Naomi W Lucchi; Venkatachalam Udhayakumar; Christopher Duplessis; Karl C Kronmann; Kwadwo A Koram
Journal:  Malar J       Date:  2013-12-17       Impact factor: 2.979

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.